Rigel(US:RIGL) Yahoo Finance·2026-01-16 15:26Core Insights - Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is recognized as one of the best-performing affordable stocks under $40, with preliminary results indicating strong revenue growth for Q4 2025 and an optimistic outlook for 2026 [1] Financial Performance - The preliminary revenue for Q4 2025 is projected to be approximately $69.8 million, an increase from $57.6 million in Q4 2024 [2] - Management anticipates gross product sales for Q4 2025 to reach $84.5 million, driven by TAVALISSE net product sales of $45.6 million, GAVRETO net product sales of $10.2 million, and REZLIDHIA net product sales of $9.6 million [2] - For the full year 2025, Rigel expects to achieve around $294.3 million in revenue, up from $179.3 million in 2024, with a projected total revenue for 2026 in the range of $275 million to $290 million [3] Market Sentiment - Following the preliminary results, Wall Street shows a bullish sentiment towards Rigel Pharmaceuticals, with Joseph Pantginis from H.C. Wainwright reiterating a Buy rating and setting a price target of $57 [3] Company Overview - Rigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on discovering and developing targeted, novel drugs in oncology, immunology, and immune oncology, with a product portfolio that includes Tavalisse, Fostamatinib, and R835 [4]